The clinical benefit of active surveillance compared to immediate therapy with curative intent has not yet been demonstrated for early-stage, localized prostate cancer, a new evidence report from AHRQ has found. Active surveillance and watchful waiting are used by physicians to monitor patients after they have been diagnosed with early-stage prostate cancer. Under active surveillance using regular monitoring, physicians immediately intervene at the earliest sign of cancer progression with treatments such as surgery or radiation therapy. Watchful waiting, in contrast, involves interventions that are implemented when symptoms develop, with the chief aim to reduce symptoms rather than cure the disease. Researchers at AHRQ’s Tufts Evidence-based Practice Center summarized existing evidence on the role of active surveillance in the management of early-stage, low-risk prostate cancer and identified that additional research is needed on observational therapies. The review was commissioned by the National Institutes of Health for presentation at its State-of-the-Science Conference on December 5–7, 2011. Select to access the report, The Role of Active Surveillance in the Management of Men With Localized Prostate Cancer.
Research Review - Final – Dec. 6, 2011
An Evidence Review of Active Surveillance in Men with Localized Prostate Cancer
This final research review is available in PDF (3.1 MB) format only. Persons using assistive technology may not be able to fully access information in this file. For assistance, please contact us
An Evidence Review of Active Surveillance in Men with Localized Prostate Cancer - Research Review - Final AHRQ Effective Health Care Program